Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.

ABSTRACT:

Importance

Tisagenlecleucel, a chimeric antigen receptor T-cell therapy for relapsed or refractory pediatric acute lymphoblastic leukemia, has been approved for use in multiple jurisdictions. The public list price is US $475 000, or more than CaD $600 000. Assessing the cost-effectiveness of tisagenlecleucel is necessary to inform policy makers on the economic value of this treatment.

Objective

To assess the value for money of tisagenlecleucel compared with current standard care for tisagenlecleucel-eligible pediatric patients with acute lymphoblastic leukemia under unknown long-term effectiveness.

Design, setting, and participants

A cost-utility analysis of tisagenlecleucel compared with current standard care using a Canadian population-based registry of pediatric pa

SUBMITTER: Furzer J 

PROVIDER: S-EPMC6990832 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature